A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed.
The aim of the study is to see how safe, tolerable, and effective REGN7945 is when given in combination with linvoseltamab, compared with linvoseltamab alone.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug(s)
* How many people treated with REGN7945 and linvoseltamab compared to linvoseltamab alone have improvement of their multiple myeloma and by how much
* How long people benefit from receiving REGN7945 in combination with linvoseltamab compared with linvoseltamab alone
* How much study drug(s) is in the blood at different times
* Whether the body makes antibodies against the study drugs(s) (which could make the study drug(s) less effective or could lead to side effects)
* If there is any change in pain and cancer-related symptoms, how well people are able to function, and their quality of life when taking the study drug(s)

Start Date11 Dec 2024

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT06140524

/ RecruitingPhase 2

Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of high-risk monoclonal gammopathy of undetermined significance (HR-MGUS) and non high-risk smoldering multiple myeloma (NHR-SMM). This requires understanding the safety and tolerability of the study drug (how the body reacts to linvoseltamab) as well as the effectiveness of the study drug (how well linvoseltamab eliminates plasma cells). All participants will start treatment with gradually increasing doses of linvoseltamab (step-up doses) before they start receiving the assigned full dose.
The study is split into 2 parts:
* In Part 1, separate groups of 3-6 patients will receive different full doses of linvoseltamab to evaluate the short-term side effects (safety) and tolerability of the study drug within the first 5 weeks after starting treatment. The data collected will help to make a decision about the dosing regimens chosen for Part 2.
* In Part 2, a larger number of participants will be randomized to different dosing regimens to further assess the side effects of linvoseltamab, and to evaluate the ability of linvoseltamab to eliminate abnormal plasma cells in HR-MGUS and NHR-SMM.
The study is looking at several other research questions, including:
* How many participants treated with linvoseltamab have improvement of their HR-MGUS or NHR-SMM?
* What side effects may happen from taking the study drug?
* How much study drug is in the blood at different times?
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).

Start Date16 Sep 2024

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT06376526

/ RecruitingPhase 2IIT

Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial COmbination Therapy to Pursue Deeper Responses with Linvoseltamab and Delay Transplant

The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects (good and bad) that Linvoseltamab has on participants and the condition.

Start Date21 Aug 2024

Sponsor / Collaborator

University of Miami

[+1]

100 Clinical Results associated with Linvoseltamab

100 Translational Medicine associated with Linvoseltamab

100 Patents (Medical) associated with Linvoseltamab

Literatures (Medical) associated with Linvoseltamab

31 Dec 2024·mAbs

Antibodies to watch in 2024

Article

Author: Crescioli, Silvia ; Kaplon, Hélène ; Reichert, Janice M. ; Wang, Lin ; Visweswaraiah, Jyothsna ; Chenoweth, Alicia

The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for 16 antibody therapeutics granted a first approval in 2023, as of November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), and divozilimab (Ivlizi)). We briefly review 26 product candidates for which marketing applications are under consideration in at least one country or region, and 23 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutic development efforts by the biopharmaceutical industry are robust and increasingly successful.

01 Nov 2024·Clinical Lymphoma Myeloma & Leukemia

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives

Review

Author: Rasche, Leo ; Waldschmidt, Johannes M ; Einsele, Hermann ; Kortüm, K Martin

Despite significant advancements, multiple myeloma (MM) remains incurable, and there is still a pressing need for new therapeutic strategies with highly selective mechanisms of action and balanced off-target toxicity. In recent years, the development of "off-the-shelf" bispecific antibodies (bsAbs) has significantly enhanced our ability to treat relapsed or refractory MM. Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Meanwhile, the range of available bsAbs is rapidly expanding, offering patients and healthcare providers a broad selection of options that vary in target antigens, binding domains, construct designs, dosing regimens, and side effects. As linvoseltamab, alnuctamab, and ABBV-383 (all BCMA × CD3), as well as forimtamig (GPRC5D × CD3) and cevostamab (FcRH5 × CD3) progress through late-stage clinical development, emerging trispecific antibodies are now available that target either 2 different MM-associated antigens or provide additional co-stimulatory signals to prevent T-cell exhaustion. Despite this plethora of therapeutic options, resistance to bsAbs is an inevitability, and the optimal positioning of these drugs within the current MM treatment landscape remains to be determined. In this review, we examine the available data on all clinically accessible bsAbs, evaluating their potential, current limitations, and implications for efficacy and safety, with the aim of achieving deeper responses and longer overall survival for MM patients.

01 Aug 2024·JOURNAL OF CLINICAL ONCOLOGY

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Article

Author: Boyapati, Anita ; Suvannasankha, Attaya ; Munder, Markus ; Dhodapkar, Madhav V. ; Shah, Mansi R. ; Wu, Ka Lung ; Chokshi, Dhruti ; Ye, Jing Christine ; Hoffman, James E. ; Maly, Joseph J. ; Houvras, Yariv ; Yancopoulos, George D. ; Martínez-Lopez, Joaquín ; Jagannath, Sundar ; Namburi, Swathi ; Baz, Rachid ; Bumma, Naresh ; Rodriguez Lorenc, Karen ; Pianko, Matthew J. ; Lee, Hans C. ; Min, Chang-Ki ; Silbermann, Rebecca ; DeVeaux, Michelle ; Byun, Ja Min ; Kroog, Glenn S. ; Vekemans, Marie-Christiane ; Lentzsch, Suzanne ; Cassady, Kaniel ; Richter, Joshua ; Hazra, Anasuya ; Sirulnik, L. Andres ; Zonder, Jeffrey A.

PURPOSE:

We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM).

METHODS:

Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR).

RESULTS:

Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time.

CONCLUSION:

Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.

News (Medical) associated with Linvoseltamab

24 Mar 2025

·www.fiercebiotech.com

Speed, Scale, and Success – The Rise of Bispecific Antibodies in Targeted Therapies

None\n Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and rare diseases. According to Research and Markets, the bispecific antibody market is experiencing rapid growth, projected to rise from $12 billion in 2024 to $50 billion by 2030, driven by over 600 ongoing clinical trials.With the increasing demand for fast-tracked drug development, researchers and biopharmaceutical companies require high-quality bispecific antibodies delivered at high speed and scale. Biointron’s bispecific antibody production service addresses this need, providing customized, scalable solutions with a 2–3 week turnaround time.The Rise of Bispecific Antibodies: A New Era in Targeted TherapiesTraditional monoclonal antibodies (mAbs), primarily immunoglobulin G (IgG), are monospecific, recognizing and binding a single antigen. In contrast, bispecific antibodies are engineered to engage two distinct targets, enabling enhanced therapeutic mechanisms such as dual inhibition, immune cell redirection, and payload delivery. These properties make BsAbs highly effective in oncology, autoimmune diseases, and infectious disease therapies.Market Expansion and Clinical AdvancementsThe bispecific antibody sector has witnessed exponential growth, with 19 bispecific antibodies approved globally and total sales surpassing $35 billion as of March 2025. The expansion is fueled by breakthrough therapies such as:Hemlibra (emicizumab, Roche) – Approved in 2018, Emicizumab is a humanized, asymmetric bispecific IgG4 antibody that binds to blood clotting factor IXa and factor X. Emicizumab is used for the treatment of patients with hemophilia A, a hereditary bleeding disorder resulting from a deficiency of blood clotting factor VIII. This BsAb replicates the function of coagulation factor VIII by promoting the formation of the prothrombinase complex and subsequent clot formation.Vabysmo (faricimab, Roche) – Approved in 2022, Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that inhibits both Ang-2 and vascular endothelial growth factor A (VEGF-A). Through VEGF-A inhibition, Faricimab reduces endothelial cell proliferation, neovascularization, and vascular permeability. It was first approved to treat neovascular age-related macular degeneration, diabetic macular edema.One example of an emerging candidate under review is Regeneron’s Linvoseltamab, an investigational, fully human, BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.The US Leads in R&D and InnovationThe United States remains the global leader in bispecific antibody R&D and commercialization, with key players such as Roche, Amgen, Pfizer, and Johnson & Johnson having strong pipelines. Since 2015, the number of bispecific antibody clinical trials has surged from fewer than 100 to over 650 in 2025, highlighting the growing significance of BsAbs in modern medicine.Speed, Scale, and Success: Why Rapid Bispecific Antibody Development MattersThe Need for Speed in Drug DevelopmentWith bispecific antibody innovation accelerating, speed has become a critical factor in drug development. Pharmaceutical companies are under pressure to advance novel therapeutics through preclinical and clinical stages before competitors. Rapid antibody production allows researchers to:Optimize lead candidates efficiently through high-throughput screening.Accelerate preclinical studies to secure early-stage funding and partnerships.Meet IND application requirements with high-purity, functionally validated BsAbs.The Role of CROs in Expediting Bispecific Antibody DevelopmentAs bispecific antibody pipelines expand, biotech and pharmaceutical companies are increasingly outsourcing development to specialized contract research organizations (CROs). CRO partnerships provide:Rapid turnaround times that internal teams may struggle to achieve.Scalable production capabilities for large-scale research programs.Access to advanced antibody engineering technologies without in-house infrastructure constraints.Biointron’s Fast-Track Bispecific Antibody Production: A Game Changer2–3 Week Turnaround: Enabling Rapid Drug DiscoveryBiointron’s streamlined bispecific antibody production service provides high-quality BsAbs in just 2–3 weeks, significantly reducing preclinical development timelines. The optimized workflow includes:Gene Synthesis & Plasmid Preparation (1 week)Codon optimization for enhanced expression.Subcloning into proprietary high-expression vectors.Plasmid amplification and purification.Transient Expression & Purification (1–2 weeks)Mammalian cell-based expression for high-yield production.Affinity purification with stringent QC (SDS-PAGE purity >95%, endotoxin <1 EU/mg).Size-exclusion chromatography (SEC-HPLC) to confirm antibody integrity.Scalability and Customization for Any Research NeedsTo support the growing demand for bispecific antibodies, Biointron offers scalable solutions tailored to diverse research needs, including:Support for all bispecific formats – IgG-like, BiTE, DVD-Ig, and more.Automated production platforms for high-throughput antibody expression.Multiple purification methods ensuring consistent quality and reproducibility.Conclusion: The Future of Bispecific Therapies Requires Speed and ScaleBiointron’s fast-track bispecific antibody production service enables researchers to accelerate preclinical research, optimize therapeutic candidates, and bring life-changing therapies to market faster. Biointron has delivered over 10,000 bispecific antibodies to global biotech and pharmaceutical companies, offering industry-leading expertise in bispecific antibody engineering, consistent, high-purity production with rapid turnaround, and end-to-end support for researchers and drug developers.Would you like to find out more about antibody production?Visit Biointron’s Learning Center or contact our expert team at info@biointron.com or +1 (732) 790 - 8340.

ImmunotherapyDrug ApprovalADC

06 Mar 2025

·pmlive.com

Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for the use of its investigational bispecific antibody linvoseltamab in multiple myeloma (MM). The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be granted conditional marketing authorisation to treat relapsed and refractory MM in adults who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have also demonstrated disease progression on their last therapy. More than 35,000 new cases of MM, an incurable blood cancer that develops in plasma cells in the bone marrow, are diagnosed every year in Europe. While current MM treatments are able to slow its progression, most patients will ultimately experience relapse and require additional therapies. Linvoseltamab is designed to bridge B-cell maturation antigen on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. The CHMP’s decision on the drug was supported by positive results from the phase 1/2 LINKER-MM1 trial, which demonstrated a 71% objective response rate at a media follow-up of 14 months, with 50% of patients achieving a complete response (CR) or better and 63% achieving a very good partial response or better. The results presented at the European Hematology Association (EHA) Congress also showed a median duration of response (DoR) of 29 months for all linvoseltamab responders, while median DoR was not reached for those who achieved a CR or better. Median progression-free survival was not reached, and median overall survival of 31 months for all patients. Suzanne Lentzsch, director of the MM and amyloidosis programme at Columbia University, said at the time of the EHA presentation in June: “Previous results from LINKER-MM1 have demonstrated that linvoseltamab has compelling efficacy characterised by deep and durable responses… Additionally, a study using US-based electronic health record data to indirectly compare linvoseltamab to real-world standard-of-care treatment also supports the overall body of evidence for this investigational medicine in heavily pretreated MM. “Collectively, these presentations underscore the exciting potential of linvoseltamab as we await decisions from regulatory authorities.” The European Commission will now consider the CHMP’s recommendation as it makes a final decision on linvoseltamab, expected in the coming months.

Clinical ResultDrug ApprovalAccelerated Approval

28 Feb 2025

·www.fiercepharma.com

Eisai, Biogen's Leqembi emerges from safety reappraisal unscathed as Europe's CHMP endorses slate of new drugs and label expansions

For Eisai and Biogen, the European Medicines Agency’s Committee for Medicinal Products for Human Use’s decision to stick by its previous call on Leqembi now punts the final approval verdict back to the European Commission, which is the ultimate authority on whether a drug scores marketing authorization in the EU. Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), drugmakers are celebrating a bevy of endorsements for big-name meds.Over the course of the sit-down, which ran from Monday through Thursday, the CHMP recommended four new drugs for approval, teed up another 16 potential label expansions and—in a major win for Eisai and Biogen—reaffirmed the positive opinion on the Alzheimer’s disease drug Leqembi (lecanemab) it first issued in November, according to the agency’s meeting summary Friday.For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on whether a drug scores marketing authorization in the EU.Despite Leqembi winning the CHMP’s favor in November—albeit in a somewhat restricted patient population—the European regulator last month said it would honor the EC’s request to consider new safety data on the antibody that surfaced after the initial thumbs-up, Biogen explained in a Friday press release.“The safety profile of lecanemab reported in clinical practice in the United States, Japan and other countries after launch is consistent with that in the approved labels, and no new safety signals are identified,” Biogen said of the situation last month. The CHMP has specifically backed Leqembi to treat mild cognitive impairment or mild dementia from Alzheimer’s but only for patients carrying one or no copy of the ApoE4 gene. Patients with two copies of the gene are at greater risk of brain swelling or bleeding side effects known as amyloid-related imaging abnormalities, according to trial data. Elsewhere, the CHMP this week advanced four new drugs for potential European approvals. Those are: Takeda’s immunoglobulin drug Deqsiga, Regeneron’s multiple myeloma antibody Lynozyfic, Krystal Biotech’s dystrophic epidermolysis bullosa gene therapy Vyjuvek and Accord Healthcare’s generic drug trabectedin, which has been endorsed in advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.As for proposed label expansions, the CHMP endorsed new uses for drugs from Vertex, Novartis, AbbVie, Eli Lilly and many other companies.In Lilly’s case, the regulator recommended approval for the company’s BTK inhibitor Jaypirca to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) who’ve already tried another medication from the same class.In addition to the new positive opinion in CLL, the drug also boasts a conditional European nod in mantle cell lymphoma, Lilly noted in a press release.AbbVie, for its part, got the CHMP’s backing in its bid to expand Rinvoq’s reach into the inflammatory disease giant cell arteritis, while Novartis’ Fabhalta received the agency’s blessing to treat adults with C3 glomerulopathy (C3G). C3G is an ultrarare kidney disease—often striking when people are young—that currently lacks any approved treatment options, Novartis said Friday.Other major label expansions that passed muster with the CHMP include those for Vertex’s Kaftrio and Kalydeco in combination to treat cystic fibrosis patients 2 and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene, plus a bid to expand the use of Valneva’s chikungunya vaccine Ixchiq to provide active immunization for kids starting at age 12. Notably, several drugmakers withdrew applications from the CHMP.Sanofi, for example, pulled the plug on efforts to score a European label expansion for Dupixent to treat moderate to severe chronic spontaneous urticaria in adults and adolescents, according to the committee's update. Plus, Spanish biotech HIPRA withdrew the application for an adapted version of its COVID-19 vaccine Bimervax targeting an updated strain of the SARS-CoV-2 virus.

Drug ApprovalVaccine

100 Deals associated with Linvoseltamab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	NDA/BLA	United States	Regeneron Pharmaceuticals, Inc.	01 Dec 2023
Relapse multiple myeloma	Phase 2	Australia	Regeneron Pharmaceuticals, Inc.	11 Dec 2024
Monoclonal Gammopathy of Undetermined Significance	Phase 2	United States	Regeneron Pharmaceuticals, Inc.	16 Sep 2024
Monoclonal Gammopathy of Undetermined Significance	Phase 2	Spain	Regeneron Pharmaceuticals, Inc.	16 Sep 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	United States	Regeneron Pharmaceuticals, Inc.	07 Aug 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	Spain	Regeneron Pharmaceuticals, Inc.	07 Aug 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	United Kingdom	Regeneron Pharmaceuticals, Inc.	07 Aug 2024
Smoldering Multiple Myeloma	Phase 2	Spain	Regeneron Pharmaceuticals, Inc.	30 Jan 2024
Refractory Multiple Myeloma	Phase 2	United States	Regeneron Pharmaceuticals, Inc.	23 Jan 2019
Refractory Multiple Myeloma	Phase 2	Japan	Regeneron Pharmaceuticals, Inc.	23 Jan 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03761108 (phase I/II first-in-human trial, Pubmed)	Phase 1/2	Multiple Myeloma high-risk cytogenetics \| penta-refractory disease	117	Linvoseltamab 50 mg	kfmmstemah(nfjdiozvgj) = bnzniiktpc absenxxbfz (vmoykzzshx ) View more	Positive	16 Jun 2024
NCT03761108 (phase I/II first-in-human trial, Pubmed)	Phase 1/2		117	Linvoseltamab 200 mg	kfmmstemah(nfjdiozvgj) = aiibrisdya absenxxbfz (vmoykzzshx ) View more	Positive	16 Jun 2024
NCT03761108 (LINKER-MM1, EHA 12024 \| EHA 22024) Manual	Phase 1/2	Multiple Myeloma	221	Linvoseltamab 200 mg	kmyemzljdg(lyyrktqpne) = nrivsrwvbc ngdrtkdmhf (yxklzrrefv ) View more	Positive	14 May 2024
NCT03761108 (LINKER-MM1, AACR2024) Manual	Phase 1/2	Multiple Myeloma	117	Linvoseltamab 200 mg	siidenlmyq(drxgupdekx) = dqfvsoxyvj upzeqgpfgy (qmpkujjoih ) View more	Positive	05 Apr 2024
NCT03761108 \| EUCTR2018-003188-78-BE (R5458-ONC-1826, ASH2023) Manual	Phase 2	Relapse multiple myeloma	117	Linvoseltamab 200 mg	kpvqvvjxkk(mtylbeults) = eipwatlmid wyfqfpbmxx (htpxwkvnlv ) View more	Positive	11 Dec 2023
	Phase 2	Relapse multiple myeloma	117	Linvoseltamab 200 mg (≥triple-class refractory)	kpvqvvjxkk(mtylbeults) = tpxypapufg wyfqfpbmxx (htpxwkvnlv ) View more	Positive	11 Dec 2023
ASH2023	Not Applicable	Multiple Myeloma	1,926	BCMA-directed BsAbs	bsgjuomwat(jqgdyehkid) = hdejjssrhg gmjmpmmprs (xzbluozgdu ) View more	-	09 Dec 2023
NCT03761108 (LINKER-MM1, GlobeNewswire) Manual	Phase 1/2	Multiple Myeloma	117	linvoseltamab 200 mg	nhduwusvtg(thusfthdcm) = ipvupxprvi sezbfsjngg (anwijdrsxk ) View more	Positive	07 Dec 2023
NCT03761108 (LINKER-MM1, IMS2023)	Phase 1/2	Relapse multiple myeloma proteasome inhibitor \| immunomodulatory drug \| anti-CD38 Ab ... View more	117	Linvoseltamab 200 mg	xknplldhys(pbehigjjuv) = vikqoqxikd ptdwojqutv (hfdqppvifi ) View more	-	26 Sep 2023
NCT03761108 (LINKER-MM1, IMS2023)	Phase 2	Multiple Myeloma \| Refractory Multiple Myeloma proteasome inhibitor \| immunomodulatory drug \| anti-CD38 Ab	221	Linvoseltamab 200 mg	blabtmytmx(otgdxmthie) = jqscjmoesg doyxywhnpm (gqiooihnoa ) View more	Positive	26 Sep 2023
NCT03761108 (LINKER-MM1, IMS2023)	Phase 2		221	Linvoseltamab 50 mg	blabtmytmx(otgdxmthie) = aioehsacbs doyxywhnpm (gqiooihnoa ) View more	Positive	26 Sep 2023
IMS2023	Not Applicable	Relapse multiple myeloma soluble BCMA	302	Linvoseltamab 200 mg	nvjzhwxosm(qdlmbkrtup) = dxplivemdw nqfcbudwzv (fwjiqnerys )	-	26 Sep 2023
NCT03761108 (LINKER-MM1, ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	Relapse multiple myeloma	252	Linvoseltamab	-	Positive	31 May 2023
NCT03761108 (LINKER-MM1, ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	Relapse multiple myeloma	252	Linvoseltamab (200mg)	pwwlmrnasr(tmubuujdea) = djlbpdmtcp fpofqnkizr (tbornnpgrb ) View more	Positive	31 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis